Last reviewed · How we verify
Mutaflor
At a glance
| Generic name | Mutaflor |
|---|---|
| Also known as | EcN, Mutaflor, Newborn, Nissle, Prophylaxis |
| Sponsor | Charite University, Berlin, Germany |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Preventing Urinary Tract Infections With E. Coli Nissle: (PHASE4)
- Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment. (PHASE4)
- Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy (NA)
- Effects of Nutritional Fat on the Growth of Intestinal E. Coli (NA)
- E. Coli Nissle in Oncology (PHASE3)
- The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study (PHASE4)
- Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II (PHASE3)
- Probiotics in the Treatment of Irritable Bowel Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mutaflor CI brief — competitive landscape report
- Mutaflor updates RSS · CI watch RSS
- Charite University, Berlin, Germany portfolio CI